最近,，英國和加拿大的研究人員合作研究發(fā)現(xiàn)，一種名為ZNF703的基因過度活躍,，會導(dǎo)致乳腺癌,。研究人員稱，這是科學(xué)家5年來發(fā)現(xiàn)的首個乳腺癌致癌基因,，對于乳腺癌的治療極具意義,。相關(guān)研究成果發(fā)表在2月18日《歐洲分子生物學(xué)學(xué)會期刊》上。
由英國劍橋大學(xué)和加拿大不列顛哥倫比亞大學(xué)的研究人員組成的研究小組,，使用微陣列芯片技術(shù),，同時對大量的細(xì)胞組織樣本測試，通過乳腺癌腫瘤細(xì)胞與正常健康細(xì)胞中基因活性的對比,，他們發(fā)現(xiàn),，一種名為ZNF703的基因在雌激素受體陽性乳腺癌腫瘤中極其活躍。通過分析,，研究人員判定,，ZNF703是一個新的雌激素受體陽性乳腺癌驅(qū)動基因,。
研究人員認(rèn)為，測試ZNF703基因活性,，有助于判斷癌癥病人腫瘤發(fā)展情況,，據(jù)此可設(shè)計(jì)針對性治療方案。而這一發(fā)現(xiàn)如經(jīng)更大規(guī)模的研究獲得證實(shí),，將為開發(fā)出新的以ZNF703基因?yàn)闃?biāo)靶的癌癥治療手段鋪平道路,。
研究論文首席作者、英國劍橋大學(xué)的卡洛斯·卡爾達(dá)斯教授指出,，通過測試這種基因的活躍程度,，可使醫(yī)生了解標(biāo)準(zhǔn)激素療法，如使用它莫西芬（一種抗雌激素）或者芳香酶抑制劑是否有效,，從而幫助醫(yī)生確認(rèn)符合病人病情的針對性藥物,。
英國癌癥研究所的萊斯利·沃爾克博士則表示，ZNF703是5年來發(fā)現(xiàn)的首個乳腺癌致癌基因,，對于開發(fā)新的乳腺癌治療藥物十分重要,，希望能藉此開發(fā)出更有效的癌癥治療手段。（生物谷Bioon.com）
生物谷推薦原文出處：
EMBO Molecular Medicine DOI: 10.1002/emmm.201100122
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium
Daniel G. Holland1,2, Angela Burleigh3,4, Anna Git1,2, Mae A. Goldgraben1,2, Pedro A. Perez-Mancera1,2, Suet-Feung Chin1, Antonio Hurtado1, Alejandra Bruna1,2, H. Raza Ali1,2, Wendy Greenwood1,2, Mark J. Dunning1, Shamith Samarajiwa1, Suraj Menon1, Oscar M. Rueda1,2, Andy G. Lynch1, Steven McKinney3,4, Ian O. Ellis5, Connie J. Eaves3,4, Jason S. Carroll1,2, Christina Curtis1,8, Samuel Aparicio3,4, Carlos Caldas1,2,6,7
Keywords:breast cancer;oestrogen metabolism;Luminal B;oncogene;ZNF703
The telomeric amplicon at 8p12 is common in oestrogen receptor-positive (ER+) breast cancers. Array-CGH and expression analyses of 1172 primary breast tumours revealed that ZNF703 was the single gene within the minimal amplicon and was amplified predominantly in the Luminal B subtype. Amplification was shown to correlate with increased gene and protein expression and was associated with a distinct expression signature and poor clinical outcome. ZNF703 transformed NIH 3T3 fibroblasts, behaving as a classical oncogene, and regulated proliferation in human luminal breast cancer cell lines and immortalized human mammary epithelial cells. Manipulation of ZNF703 expression in the luminal MCF7 cell line modified the effects of TGFβ on proliferation. Overexpression of ZNF703 in normal human breast epithelial cells enhanced the frequency of in vitro colony-forming cells from luminal progenitors. Taken together, these data strongly point to ZNF703 as a novel oncogene in Luminal B breast cancer.
